What is JBIO's return on equity?

JBIO (JBIO) reported return on equity of -132.5% in Q2 2025.

How has JBIO's return on equity changed year-over-year?

JBIO's return on equity decreased by 47.5% year-over-year, from -89.8% to -132.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

JBIO JBIO Return on equity

Return on equity at other companies

Vertex PharmaceuticalsVRTX

24.2%—

Travere Therapeutics, Inc.TVTX

-706%-1,302pp

Vera TherapeuticsVERA

-71.3%+296pp

AnaptysBio, Inc.ANAB

-343.8%-1,012pp

Cullinan Therapeutics, Inc.CGEM

-44%+26.2pp

Viridian Therapeutics, Inc.VRDN

-58.1%+7.9pp

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B—

Enterprise value$1.28B—

Returns & leverage

See full

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

net income/total stockholders equity=-132.5%

Based on trailing twelve months.

The official record: JBIO’s 10-Q, filed August 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about JBIO's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's return on equity?: JBIO (JBIO) reported return on equity of -132.5% in Q2 2025.
How has JBIO's return on equity changed year-over-year?: JBIO's return on equity decreased by 47.5% year-over-year, from -89.8% to -132.5%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.